Beyond T and NK cells, other immune cells can be used for cell therapies in solid tumours
How do we improve CAR-T cell therapy in CLL? A look at clinical data plus a new thought leader interview in the space.
Review of a round dozen key abstracts at #ASH18, both scientific and clinical data is under the microscope!
We offer 13 key highlights from day 2 of ASH18, including some surprises.
Highlights from Day 1 of the 2018 ASH conference held in San Diego
From one BCMA directed CAR in 2015, we now have a very competitive niche in multiple myeloma. What's in store?
What to watch out for in the ASH18 LBA session
A top-line review of the ASH18 abstract palooza